Endocrine therapies and QTc prolongation

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• The QT interval reflects ventricular cardiac repolarization.
• Prolonged QT intervals can lead to fatal arrhythmias like torsades de pointes.
• Certain endocrine disorders and their treatments are associated with QTc alterations.

Purpose of the Study:

• To review the QTc prolongation potential of widely used endocrine drugs.
• To highlight the interplay between endocrine diseases, drug clearance, and cardiac repolarization.

Main Methods:

• Literature review of drugs used in endocrinology.
• Analysis of studies reporting QTc interval changes associated with these drugs.
• Consideration of patient-specific factors like endocrine disease and drug metabolism.

Main Results:

• Several classes of endocrine medications, including antidiabetics, lipid-lowering agents, and thyroid/adrenal drugs, are linked to QTc prolongation.
• Endocrine diseases can impair drug clearance and reduce repolarization reserve, exacerbating QTc risks.
• Individual drug effects and patient comorbidities significantly influence QTc interval behavior.

Conclusions:

• Clinicians must be aware of the QTc prolongation risks associated with common endocrine drugs.
• Careful patient selection and monitoring are crucial when prescribing these agents, especially in those with endocrine conditions.
• Further research is needed to fully elucidate the mechanisms and clinical implications of QTc prolongation in endocrinology.